ProQR Therapeutics (PRQR) Profit After Tax (2012 - 2026)

ProQR Therapeutics has reported Profit After Tax for 15 years, with the latest figure at -$15.7 million in Q1 2026.

• Quarterly Profit After Tax fell 47.79% year-over-year to -$15.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$77.3 million (down 61.78% YoY) and the FY2025 annual result came in at -$49.1 million, down 65.51% from the prior year.
• Profit After Tax improved to -$15.7 million in Q1 2026 per PRQR's latest filing, from -$89.1 million in the prior quarter.
• Over five years, Profit After Tax peaked at $23.5 million in Q3 2022 and troughed at -$115.9 million in Q4 2022.
• A 5-year average of -$11.2 million and a median of $2.9 million in 2024 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2024 and 2025: Profit After Tax tumbled 830.01% in 2024, then soared 402.18% in 2025.
• Over 5 years, Profit After Tax stood at -$115.9 million in 2022, then jumped by 95.42% to -$5.3 million in 2023, then sank by 830.01% to -$49.4 million in 2024, then slumped by 80.35% to -$89.1 million in 2025, then surged by 82.41% to -$15.7 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$15.7 million, -$89.1 million, and $12.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.